Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 85

recruiting
3 975
countries
28
conditions
2 106

1 514 trials match your criteria

Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Inupadenant Hydrochloride

Study on the Effects of Ianalumab in Adults with Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Sjögren’s Disease

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:CzechiaCzechia
  • Participants:65+ years
  • Substances:BI 1015550

Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:CLS12311

Study of emapalumab in children and adults with Macrophage Activation Syndrome (MAS) occurring in Still's Disease or Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emapalumab

Arterial disorder+1

Not recruiting

Study on Cerebrolysin and Sodium Chloride for Patients with CADASIL

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Plasma cell myeloma

Not recruiting

Study on the Effects of Isatuximab with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Colitis ulcerative

Not recruiting

Study on the Effects of Tamuzimod in Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tamuzimod Acetate

Study of belantamab mafodotin, bortezomib and dexamethasone combination in adults with relapsed or refractory multiple myeloma who received at least one prior therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Study on Elamipretide for Patients with Dry Age-Related Macular Degeneration (Dry AMD)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Elamipretide Trihydrochloride
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.